Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 69

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 69
---
Co or the Sponsor in connection with such waiver.

Management and Board of Directors Following the Business Combination

In connection with the closing, all of the officers and directors of Iris will resign and Mr. Chris Kim will be appointed as the President and Chief Executive Officer, Mr. Scott Dam will be appointed as Chief Financial Officer, Mr. Byong C. Yoo will be appointed Chief Science Officer, Mr. Sang-jin Daniel Lee will be appointed Head of Research and Development, and Mr. Beom K. Choi, will be appointed as Chief Technology Officer. Effective as of the closing, the ParentCo Board will consist of four members, of which three members will be designated by Liminatus and one member will be designated by Iris. See section titled “ Management of ParentCo Following the Business Combination ” for additional information.

#### Redemption Rights
Pursuant to our charter and the Trust Agreement, eligible holders of the Iris Class A Shares may elect to have their shares redeemed for cash at a redemption price per share calculated in accordance with our charter, by tendering the Iris Class A Shares of such holder for redemption not later than 5:00 p.m. Eastern Time on the date that is two Business Days prior to the date of the Special Meeting. As of January 2, 2025, this would have amounted to approximately $11.47 per share (net of all applicable taxes payable from the Trust Account). If a holder of public shares properly exercises his, her or its redemption rights, then such holder will be exchanging his, her or its shares of Iris Class A Common Stock for cash and will no longer own such shares. See the section entitled “ Special Meeting of Iris Stockholders — Redemption Rights and Procedures ” for procedures to be followed if you wish to redeem your shares for cash and not own the ParentCo common stock following consummation of the Business Combination.

After the special meeting held by Iris on December 20, 2024, to vote upon a charter amendment to extend the time to complete a business combination until March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board), public stockholders elected to redeem 64,453 shares of common stock, resulting in $2,001,033 of funds remaining in the Trust Account (as adjusted for redemptions paid out of the Trust Account in January 2025 and subject to adjustment for such further taxes as may be payable from the Trust Account) and 174,477 shares of Iris common stock held by the public